Clinical Trial Detail

NCT ID NCT03502681
Title A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Monika Joshi, MD
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Avelumab + Eribulin

Age Groups: senior adult

No variant requirements are available.